(redirected from Ultravate)


a very high potency synthetic corticosteroid used topically in the form of the propionate as an antiinflammatory and antipruritic agent.
Miller-Keane Encyclopedia and Dictionary of Medicine, Nursing, and Allied Health, Seventh Edition. © 2003 by Saunders, an imprint of Elsevier, Inc. All rights reserved.


(hal-oh-bay-ta-sol) ,


(trade name)


Therapeutic: anti inflammatories steroidal
Pharmacologic: corticosteroids
Pregnancy Category: C


Management of inflammation and pruritis associated with various allergic/immunologic skin problems.


Suppresses normal immune response and inflammation.

Therapeutic effects

Suppression of dermatologic inflammation and immune processes.


Absorption: Minimal. Prolonged use on large surface areas or large amounts applied or use of occlusive dressings may increase systemic absorption.
Distribution: Remains primarily at site of action.
Metabolism and Excretion: Usually metabolized in skin.
Half-life: Unknown.

Time/action profile (response depends on condition being treated)



Contraindicated in: Hypersensitivity or known intolerance to corticosteroids or components of vehicles (ointment or cream base, preservative, alcohol); Untreated bacterial or viral infections.
Use Cautiously in: Hepatic dysfunction; Diabetes mellitus, cataracts, glaucoma, or tuberculosis (use of large amounts of high-potency agents may worsen condition); Patients with pre-existing skin atrophy; Pregnancy, lactation, or children (chronic high-dose usage may result in adrenal suppression in mother, growth suppression in children; children may be more susceptible to adrenal and growth suppression).

Adverse Reactions/Side Effects


  • allergic contact dermatitis
  • atrophy
  • burning
  • dryness
  • edema
  • folliculitis
  • hypersensitivity reactions
  • hypertrichosis
  • hypopigmentation
  • irritation
  • maceration
  • miliaria
  • perioral dermatitis
  • secondary infection
  • striae


  • adrenal suppression (use of occlusive dressings, long-term therapy)


Drug-Drug interaction

None significant.


Topical (Adults) Apply to affected area(s) 1–2 times daily.


Cream: 0.05%
Ointment: 0.05%

Nursing implications

Nursing assessment

  • Assess affected skin prior to and daily during therapy. Note degree of inflammation and pruritus. Notify physician or other health care professional if symptoms of infection (increased pain, erythema, purulent exudate) develop.
  • Lab Test Considerations: Periodic adrenal function tests may be ordered to assess degree of hypothalamic-pituitary-adrenal (HPA) axis suppression in chronic topical therapy if suspected. Children and patients with dose applied to a large area, using an occlusive dressing, or using high-potency products are at highest risk for HPA suppression.
    • May cause increased serum and urine glucose concentrations if significant absorption occurs.

Potential Nursing Diagnoses

Risk for impaired skin integrity (Indications)
Risk for infection (Side Effects)
Deficient knowledge, related to medication regimen (Patient/Family Teaching)


  • Choice of vehicle depends on site and type of lesion. Ointments are more occlusive and preferred for dry, scaly lesions. Creams should be used on oozing or intertriginous areas, where the occlusive action of ointments might cause folliculitis or maceration. Creams may be preferred for aesthetic reasons even though they may be more drying to skin than ointments.
  • Topical: Apply ointmentand cream sparingly as a thin film to clean, slightly moist skin. Wash hands immediately after application. Apply occlusive dressing only if specified by physician or other health care professional.

Patient/Family Teaching

  • Instruct patient on correct technique of medication administration. Emphasize importance of avoiding the eyes. If a dose is missed, it should be applied as soon as remembered unless almost time for the next dose.
  • Caution patient to use only as directed. Avoid using cosmetics, bandages, dressings, or other skin products over the treated area unless directed by health care professional.
  • Caution women that medication should not be used extensively, in large amounts, or for protracted periods in patients who are pregnant or planning to become pregnant.
  • Advise patient to consult health care professional before using medicine for condition other than indicated.
  • Instruct patient to inform health care professional if symptoms of underlying disease return or worsen or if symptoms of infection develop.

Evaluation/Desired Outcomes

  • Resolution of skin inflammation, pruritus, or other dermatologic conditions.
Drug Guide, © 2015 Farlex and Partners
References in periodicals archive ?
M2 EQUITYBITES-November 27, 2018-Perrigo awarded US FDA tentative approval for first to file generic Ultravate Lotion 0.05%
Healthcare company Perrigo Company plc (NYSE:PRGO) (TASE:PRGO) reported on Tuesday the receipt of tentative approval from the US Food and Drug Administration for the first to file generic version of Ultravate Lotion (halobetasol propionate) 0.05%.
The company added that the Ultravate Lotion, 0.05% is indicated for the topical treatment of plaque psoriasis in patients 18 years of age and older.
Global Banking News-November 27, 2018-Perrigo awarded US FDA tentative approval for first to file generic Ultravate Lotion 0.05%
M2 PHARMA-November 27, 2018-Perrigo awarded US FDA tentative approval for first to file generic Ultravate Lotion 0.05%
Halobetasol propionate Taro Pharmaceuticals Ultravate
Halobetasol propionate Agis Industries Ultravate cream
For (Ultravate) times daily relatively severe flares.
$22.94 (15 g) propionate fluticasone 0.05% cream or 0.005% ointment $21.05 (15 g) propionate applied 1-2 times daily (Cutivate) applied 1-2 times daily halobetasol 0.05% applied 1-2 times daily $30.62 (15 g) propionate (Ultravate) hydrocortisone 1% applied 2-3 times daily $2.89 (30 g) mometasone 0.1% applied once daily $22.43 (15 g) furoate (Elocon) triamcinolone 0.1% applied b.i.d.
Fougera has also introduced halobetasol cream 0.05% and ointment 0.05%, AB rated to Ultravate (Westwood-Squibb Pharmaceuticals Inc.).